Filing Details

Accession Number:
0001104659-15-021407
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-20 16:20:07
Reporting Period:
2015-03-18
Filing Date:
2015-03-20
Accepted Time:
2015-03-20 16:20:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1264587 Stemline Therapeutics Inc STML Pharmaceutical Preparations (2834) 450522567
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1251213 Ron Bentsur C/O Stemline Therapeutics, Inc.
750 Lexington Avenue, Eleventh Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-18 5,421 $4.09 8,673 No 4 M Direct
Common Stock Disposition 2015-03-18 1,388 $16.12 7,285 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2015-03-18 5,421 $0.00 5,421 $4.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-04-01 No 4 M Direct
Footnotes
  1. In connection with the exercise of expiring stock options, 1,388 shares were sold to satisfy the exercise price.
  2. Reflects the weighted average sale price. The range of prices for such transaction is $16.12 to $16.13. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
  3. The options vested in full on April 10, 2010.